Aardvark Therapeutics, Inc. AARD
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -90.76% | -152.05% | -- | -- | -- |
| Total Depreciation and Amortization | 31.25% | 121.05% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 601.48% | 437.80% | -- | -- | -- |
| Change in Net Operating Assets | -325.34% | 838.92% | -- | -- | -- |
| Cash from Operations | -110.88% | -125.96% | -- | -- | -- |
| Capital Expenditure | 96.08% | 8.65% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 201.34% | 178.15% | -- | -- | -- |
| Cash from Investing | 201.24% | 178.00% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.22% | -99.50% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 98.64% | -- | -- | -- |
| Cash from Financing | -99.19% | -99.78% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 179.52% | 89.47% | -- | -- | -- |